Clinical Trial

A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multi-center, randomized, double-blind, parallel, placebo-controlled phase 2 clinical study. A total of 403 adult participants with moderate to severe AD are planned to be enrolled to evaluate efficacy, safety, PK characteristics, immunogenicity, and changes in PD characteristics of IBI356.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-29.
Status change: Not Yet Recruiting → Recruiting 2026-03-10
Trial Details
NCT Number NCT07330934
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Atopic Dermatitis
Enrollment 403 participants
Start Date 2025-12-31
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-11